Sarepta Therapeutics has entered into a settlement agreement with REGENXBIO Inc. and the University of Pennsylvania (UPenn) to resolve pending patent infringement litigations. The agreement addresses disputes over patents related to the AAVrh74-based capsid technology used in Sarepta's gene therapy products, including its key product, ELEVIDYS.
Key Details
- Settlement Payment: Sarepta will make a one-time, lump-sum payment of $39.0 million to REGENXBIO within ten days of the agreement's effective date of September 23, 2026.
- Agreement Scope: REGENXBIO and UPenn have released Sarepta from past infringement claims and agreed not to sue in the future over certain patents related to any Sarepta gene therapy product using the AAVrh74-based capsid.
- Financial Impact: Sarepta had previously recorded a $39.0 million litigation contingency charge in Q2 2026 in anticipation of this settlement.